Related Experiment Video
Updated: Aug 2, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Molecular genetics of cutaneous lymphomas
1Skin Tumour Unit, St. John's Institute of Dermatology, St. Thomas' Hospital, London, UK. seanwhittaker@doctors.org.uk
Abstract:
The underlying molecular basis of primary cutaneous lymphomas has not yet been clarified. However, abnormalities of cell cycle control genes and well-defined tumor suppressor genes such as p53 are common and may contribute to disease progression and treatment resistance. Biallelic inactivation of tumor suppressor genes usually occurs by a combination of deletion, point mutation, and/or promotor hypermethylation. The detection of UVB-specific mutations of p53 requires confirmation but may have important implications for the management of patients with mycosis fungoides. Molecular cytogenetic studies have identified common regions of chromosomal deletion and amplification, which suggests the presence and location of genes that are of critical importance in the pathogenesis of cutaneous lymphoma.
Insights
The molecular basis of primary cutaneous lymphomas remains unclear. Tumor suppressor gene abnormalities, like p53 mutations, are common and impact disease progression and treatment resistance in cutaneous lymphoma.
Area of Science:
- Oncology
- Dermatology
- Molecular Biology
Background:
- The molecular underpinnings of primary cutaneous lymphomas are not fully understood.
- Abnormalities in cell cycle control and tumor suppressor genes, such as p53, are frequently observed.
- These genetic alterations are implicated in disease progression and resistance to treatment.
Purpose of the Study:
- To investigate the molecular basis of primary cutaneous lymphomas.
- To identify key genetic alterations contributing to the pathogenesis of these cancers.
- To explore the role of p53 mutations and chromosomal abnormalities.
Main Methods:
- Analysis of cell cycle control genes and tumor suppressor genes, including p53.
- Investigation of mechanisms of biallelic inactivation (deletion, point mutation, hypermethylation).
- Molecular cytogenetic studies to identify chromosomal deletions and amplifications.
Main Results:
- Common abnormalities in cell cycle control and tumor suppressor genes, particularly p53, were identified.
- Mechanisms like deletion, point mutation, and hypermethylation contribute to tumor suppressor gene inactivation.
- UVB-specific p53 mutations may be relevant, requiring further confirmation.
- Molecular cytogenetics revealed common chromosomal deletion and amplification regions.
Conclusions:
- Genetic abnormalities, especially involving p53 and chromosomal alterations, play a critical role in cutaneous lymphoma pathogenesis.
- Understanding these molecular changes is crucial for managing patients and developing targeted therapies.
- Further research into UVB-specific p53 mutations could refine treatment strategies for mycosis fungoides.
